Ovarian Cancer Symposium

Professor Charlie Gourley

Clinical Director, Cancer Research UK Edinburgh Centre 

Professor and Honorary Consultant in Medical Oncology, The University of Edinburgh

Molecular stratification of endometrioid ovarian carcinoma

Dr Kathleen N. Moore, MD, MS

Associate Director Clinical Research,
Associate Professor, Section of Gynecologic Oncology,

Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center

Changes and challenges in the treatment paradigm for front line ovarian cancer.

Dr Ahmed Ahmed, MD, PhD

Professor of Gynaecological Oncology, Director of the Ovarian Cancer Cell Laboratory, University of Oxford

The Oxford Classic and the story of the “SPARC cluster”.

Dr Alan D. D'Andrea, MD

Director, Center for DNA Damage and Repair,

Director, Susan F. Smith Center for Women’s Cancers at the Fuller-American Cancer Society

Professor, Harvard Medical School, Dana-Farber Cancer Institute, Boston

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous Recombination-Deficient Tumour.

Dr Elise Kohn, MD CAPT, USPHS, Fellow AAAS

Head, Gynecologic and Neuroendocrine Cancer Therapeutics

Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute

Not your average DNA damage: leveraging underlying DNA repair dysfunction for benefit.